A Near-Infrared Light-Activated Photocage Based on a Ruthenium Complex for Cancer Phototherapy.
Angew Chem Int Ed Engl
; 62(24): e202218768, 2023 06 12.
Article
en En
| MEDLINE
| ID: mdl-36890113
ABSTRACT
Conventional photocages only respond to short wavelength light, which is a significant obstacle to developing efficient phototherapy in vivo. The development of photocages activated by near-infrared (NIR) light at wavelengths from 700 to 950â
nm is important for in vivo studies but remains challenging. Herein, we describe the synthesis of a photocage based on a ruthenium (Ru) complex with NIR light-triggered photocleavage reaction. The commercial anticancer drug, tetrahydrocurcumin (THC), was coordinated to the RuII center to create the Ru-based photocage that is readily responsive to NIR light at 760â
nm. The photocage inherited the anticancer properties of THC. As a proof-of-concept, we further engineered a self-assembled photocage-based nanoparticle system with amphiphilic block copolymers. Upon exposure to NIR light at 760â
nm, the Ru complex-based photocages were released from the polymeric nanoparticles and efficiently inhibited tumor proliferation in vivo.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fotoquimioterapia
/
Rutenio
/
Nanopartículas
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Angew Chem Int Ed Engl
Año:
2023
Tipo del documento:
Article
País de afiliación:
China